Generation of Lung Epithelium from Pluripotent Stem Cells
- First Online:
- Cite this article as:
- Wong, A.P. & Rossant, J. Curr Pathobiol Rep (2013) 1: 137. doi:10.1007/s40139-013-0016-9
- 1.6k Views
The understanding of key processes and signaling mechanisms in lung development has been mainly demonstrated through gain and loss of function studies in mice, while human lung development remains largely unexplored due to inaccessibility. Several recent reports have exploited the identification of key signaling mechanisms that regulate lineage commitment and restriction in mouse lung development, to direct differentiation of both mouse and human pluripotent stem cells towards lung epithelial cells. In this review, we discuss the recent advances in the generation of respiratory epithelia from pluripotent stem cells and the potential of these engineered cells for novel scientific discoveries in lung diseases and future translation into regenerative therapies.
KeywordsLungEmbryonic stem cellsInduced pluripotent stem cellsCystic fibrosisLung developmentAirway epitheliumPathobiology
Lung diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are major health issues for children and adults. Currently the biological understanding of the etiology of many of these diseases is still minimal. Therapeutic interventions are largely based on treating symptoms, not addressing root causes. While such therapies have improved outcomes and increased quality of life, long-term outcomes are still poor. Presently, lung transplantation is the treatment of choice for end-stage lung disease. However, the shortage of donor lungs and the increased risk of secondary complications such as graft rejection and failure [1–3] means that transplantation is a temporary fix.
New strategies to use stem cells to regenerate or generate new lung epithelia have been of growing interest. This review discusses some of the most recent advances in generating lung epithelial cells from pluripotent stem cells and how these newly engineered cells can be used to find new therapies for lung diseases.
Embryonic Origins of the Lung
As the lung matures, cell turnover decreases  and is very slow in the fully mature adult lung . While studies have shown some regenerative potential of the fetal and adult lung following injury [8–12], failure of the lung to repair itself often results in chronic inflammation, disease progression and pathogenesis. Strategies to repair injured lungs, by activating resident lung stem cells [13–16] or by grafting bone marrow-derived stem cells [17–19] have shown some success but need to be further validated. A more direct approach based on driving differentiation of pluripotent stem cells towards the different lung epithelial cell types clearly holds promise. However, early efforts to differentiate embryonic stem cells into pulmonary cells showed limited success [20–23]. More recent studies have taken a step-wise approach based on mimicking the stages of normal lung development and have achieved more promising results. Here we provide a brief overview of these studies, and discuss the potential use of these cells for regenerative medicine and drug discovery. For more detailed descriptions of early endoderm and embryonic lung development please refer to other reviews [5•, 24•, 26•, 27]
Comparative Lung Development
While the phases of lung development are similar between mice and human, the timelines of lung development are quite different. In the mouse, embryonic lung development begins around embryonic day 9 and maturation of the lung is complete about 30 days postnatally. In contrast, each phase of fetal lung development in humans is measured in weeks and complete maturation of the airways is not achieved until up to 2 years post-natally [26•]. In addition, there are clear differences in anatomical and regional distribution of the cell types from the large airways through to the intralobar airway epithelium between mouse and human [12, 28–33]. The current knowledge of lung development is largely based on gain- and loss-of-function studies in mice [5•, 25, 26•, 27, 34, 35]. This knowledge has been the basis of attempts at directed differentiation of stem cells to lung epithelium. Comparative studies of lung differentiation from mouse and human pluripotent cells have suggested that the general rules of differentiation are similar. However, the fine details may differ in ways that could have significance for the sought-for regenerative outcomes. Careful study of the development of different lung cell types from stem cells of mouse and human origin may help reveal the underlying similarities and differences in terms of timing, marker expression and potentially even differentiation pathways.
Directed Differentiation of Pluripotent Stem Cells to Lung Epithelial Cells
Using embryonic stem cells derived from a mouse line carrying an Nkx2.1–GFP reporter, Longmire et al. [38••] adopted the step-wise protocol from Green et al. [36••] to generate ventral foregut endoderm with the exception that they also included a high concentration of FGF2. Interestingly, exposure of definitive endoderm cells to NOGGIN and SB431452 alone was sufficient to induce GFP expression in up to 21 % of the cells. Gene expression profiling of the sorted GFP+ cells after treatment with Wnt3a, FGF10, KGF, BMP4, EGF and FGF2 revealed up-regulated expression of both lung and thyroid lineage genes. Further differentiation of the cells with FGF2, FGF10, and a mixture of KGF, dexamethasone, cAMP and IBMX (also known as DCI and previously shown to induce transcriptomic changes in fetal lung epithelial cells [39, 40]), resulted in down-regulation of Nkx2.1 in approximately half of the cells. Of the Nkx2.1-negative population, up to 40 % expressed a marker associated with Type I alveolar cells (Pdpn or T1a). Of the Nkx2.1-positive cells, some cells expressed the pro-form of SFTPC, suggestive of Type II cells. Recellularization of decellularized mouse lungs with Nkx2.1–GFP+ cells showed some engraftment of these donor cells as Type I T1a-expressing cells in the parenchyma.
Mou et al. [41••] used a slightly different approach to generate multipotent lung and airway progenitors from mouse and human pluripotent stem cells. Starting with a monolayer method of differentiation, Mou et al. . adapted a previously published method of generating definitive endoderm with high efficiency. Unlike the studies by Green et al., and Longmire et al., TGFβ inhibition with SB431452 alone was sufficient to induce anterior patterning of the definitive endoderm cells. Following the addition of BMP4, FGF2 and a GSK3 inhibitor, up to 10 and 30 % of Nkx2.1 expressing cells were observed with mouse cells and human induced pluripotent stem (iPS) cells, respectively. To generate airway progenitors from the Nkx2.1-expressing cells, a combination of retinoic acid, BMP7, KGF, Wnt antagonism and MAPK/ERK inhibition was used. This produced up to 18 % Nkx2.1+ Sox2+ proximal progenitors in the population of cells. Of the total Nkx2.1+ population, a smaller percentage (1–4 %) also expressed p63, a marker associated with conducting airway basal cells . Interestingly, using an in vivo model of differentiation with a mixed population of lung endoderm cells in matrigel and injected subcutaneously in immunodeficient mice, epithelial spheres were observed that contained Clara cell, ciliated cell, goblet cell and basal cell lineages. The efficiency of differentiation both in vivo and in vitro appears low and while proximal cell lineages were established, distal lung parenchymal epithelia characterized by Type I and Type II cells were not generated even though Nkx2.1+ Sox9+ or Nkx2.1+ FoxP2+ multipotent distal progenitor cells were established.
Two recent publications have bypassed the early stepwise differentiation process and showed some success in generating distal respiratory epithelial cell types. Schmeckebier et al.  recently reported that KGF, a known epithelial mitogen  that can promote maturation of Type II fetal rat alveolar cells , can induce differentiation and maturation of mouse ES and iPS-derived Type II cells in combination with glucocorticoids, cAMP-derivatives and compounds that elevate cAMP levels. While Longmire et al., used DCI and KGF to induce alveolar differentiation from lung endoderm progenitors, Schmeckebier et al., added KGF early in the differentiation process from embryoid bodies, followed by addition of DCI and KGF at day 14. They report a 14-fold greater expression of SP-C and fivefold greater expression of aquaporin-5 (Type I alveolar cell marker) compared to unstimulated controls within 10 days. Electron microscopy revealed features of Type II alveolar cell structures such as apical microvilli and electron-dense lamellar bodies.
Another study by Siti-Ismail et al.  reported an impressive ability to generate Type II cells that does not rely on addition of defined exogenous growth factors, but rather on a bioengineering process utilizing encapsulation of mES cells in hydrogels and culture in conditioned media from an alveolar cancer cell line (A549) in a rotary bioreactor . In as little as 5 days, up to 50 % of the cells were reported to be Type II alveolar cells that under electron microscopy exhibited ultrastructural features such as microvilli and lamellar bodies. Furthermore, these cells could be maintained in the bioreactor for 100 days and plated onto 2D cultures without differentiating into Type I cells. It would be interesting to know how well these engineered Type II cells integrate and function in vivo in respiratory epithelia and whether human pluripotent stem cells can also be differentiated as efficiently using this method.
Rather than focus on distal alveolar epithelium, we recently outlined an in vitro differentiation protocol for generating proximal airway epithelia from human pluripotent stem cells, the cell population that is most affected in CF patients. The cystic fibrosis transmembrane conductance regulator (CFTR) protein channel [48••] is involved in chloride and water transport across the airway epithelium. Mutations in this gene lead to failure to maintain proper mucociliary transport and clearance of pathogens. In our step-wise differentiation process, pluripotent stem cells were induced to differentiate progressively into definitive endoderm, anterior foregut endoderm, proximal epithelial progenitors, followed by proliferation, maturation and polarization of the proximal epithelia in an air–liquid interface. The result was maturation of patches of tight junction-coupled differentiated airway epithelial cells. These cells showed up-regulated expression of several characteristic proximal large airway markers, including the polarized apical localization of the CFTR protein needed for proper chloride transport. The CFTR transport functions were active in the differentiated cells as demonstrated by responsiveness to cAMP agonists and a CFTR potentiator in a modified iodide efflux assay for CFTR activity. This study also showed generation of mature airway epithelia from human iPS cells, derived from CF patients. Analysis of these cells shows great promise to study the role of unique genetic modifiers in CFTR activity [49–51] especially since treatment of the CF-iPS-derived airway epithelial cells with a small molecule compound, C18, resulted in partial correction of the CFTR protein in the plasma membrane, suggesting that these cells could be used to model CF in vitro.
It should be noted, however, that this protocol, while successful in generating around 40–50 % CFTR+ polarized lung epithelial cells, still results in a heterogeneous mixture of other endoderm cell types. To date, there has not been a lung differentiation protocol reported that produces a homogeneous cell type of interest. Future refinements, including sorting appropriate cells at appropriate stages of the differentiation protocol, will be needed to solve the heterogeneity issue. Furthermore, while functional activity of CFTR showed levels similar to control epithelial cell lines, future studies will also need to determine the similarities between CFTR function from iPS-derived cells compared to normal post-natal bronchial primary epithelial cells.
Application of Engineered Lung Cells
Recent advances in generating airway and distal lung epithelial cells and the ability to generate a renewable source of these cells in vitro offers great hope in using these cells to study lung diseases. Reprogramming of somatic cells into induced pluripotent stem (iPS) cells has created a powerful and unlimited source of patient-specific cells bearing many pulmonary congenital defects [41••, 48••, 52]. These cells carry the mutation that causes or is associated with the disease and can be used to model the disease in vitro. The ability to generate tissue-specific cells from iPS cells offers great opportunities to model many lung diseases in vitro, including the pathogenesis of lung diseases caused by respiratory infections and other congenital defects such as surfactant protein deficiency . For the latter, the lack of reliable methods to generate Type II alveolar cells from human iPS cells remains an impediment to progress towards an in vitro model of this lung disease. A promising example of an application of iPS for disease modeling is CF, which is the most common life shortening congenital disease amongst Caucasians. The disease affects epithelial tissues lining multiple organs throughout the body, including the airways, skin, intestines, pancreatic ducts, and reproductive organs. Lack of ion transport across the airway epithelium leads to improper airway fluid balance, mucous thickening and defective mucociliary clearance, thereby creating a niche for chronic bacterial infections in the airways. These infections are the main cause of mortality in CF patients. Modeling CF has been difficult. The traditional CF knockout mouse model does not recapitulate the pulmonary aspect of the disease, and the availability of patient-specific CF lung epithelium is limiting for in vitro studies. Other animal models of CF, such as swine  and ferret , display airway phenotypes similar to humans and are useful surrogates for some human studies. However, they cannot model the genetic heterogeneity in disease outcome shown in humans. Patients carrying the same CF mutation will have varying degrees of disease progression and responses to therapy. This is in part due to genetic modifiers that have been shown to affect disease progression [49, 56, 57]. Generation of CF patient iPS cell-derived airway cells in vitro is thus a critical tool for studying the molecular pathways, the effects of environmental insults and the genetic modifiers of CF pathogenesis.
Patient-derived induced iPS cells hold great promise for patient-specific drug discovery. The most common CF mutation (~70 % of cases) in the CF gene is caused by a trinucleotide in-frame deletion at position 508 (F508del) of the peptide sequence . Consequently the mutant CFTR protein does not fold properly in the endoplasmic reticulum and is rapidly targeted for degradation instead of translocating to the cell membrane for chloride transport. Recent studies have shown that small molecules called “corrector” compounds are effective in rescuing some of the mutant defects in protein processing and trafficking [59–61]. As a proof-of-concept, we recently reported that CF-iPSC-derived lung epithelial cells could be used to validate novel CF corrector compounds. An active analog of the small molecule VX-809 (vertex 809 currently in phase II clinical trials) promoted plasma membrane accumulation of the mature complex glycosylated form of CFTR protein (band C) in F508del CF-iPS cell-derived lung epithelial cells [48••]. The CF patient iPS cell-derived airway epithelial cells therefore provide a novel platform for cell-based patient-specific screens to find new treatments for CF and other airway diseases [49, 56, 57]
Small molecule screening could also be used to identify novel compounds that improve the directed differentiation of iPS cells to lung epithelial cells. Current differentiation methods use recombinant proteins from xenobiotic sources (bacteria or insect cells) and have high batch to batch variability. In addition, the cost of these recombinant proteins can be astronomical if scale-up of the differentiation process was needed for regenerative purposes. Small molecules, therefore, can be used to improve and control the cell differentiation process. Use of less economical, but highly efficient and reproducible compounds, has been previously shown by Borowiak et al.  in driving definitive endoderm in mouse and human ESC and by Chen et al.  in driving human ESC into pancreatic progenitors. Small molecules can theoretically be used to generate specific lung progenitor populations or direct certain lung lineages over others.
Overall, the ability to generate a renewable source of airway epithelial cells from pluripotent stem cells holds great promise for high-content screens for therapy.
Cell replacement strategies have shown some success in several models of lung injury [64–66]. Regeneration by extrapulmonary sources such as the bone marrow [18, 67–69] and cord blood [70, 71] have identified these cells as potential sources of stem cells for therapeutic strategies. Bioengineering of lung organoids using simple biodegradable scaffolds seeded with fetal lung cells [72–74] is also a promising new avenue for tissue replacement approaches. However, use of these scaffolds to differentiate and support non-lung-derived cells such as pluripotent stem cells has yet to be determined. One of the limitations in these organoid cultures is the importance of mechanical stretch in activating pathways involved in epithelial differentiation and proliferation [75–77].
Recent advances in the decellularization of the lung may provide a more plausible system since most of the lung extracellular matrices are preserved and allow initial binding of the donor cells to the lung tissue [78–81]. In 2010, two seminal papers by Ott et al.  and Petersen et al.  demonstrated that cadaveric rat lungs could be safely decellularized leaving most of the extracellular matrix intact and then using a bioreactor, recellularized with epithelial and endothelial cells. Petersen et al.  showed that the engineered lungs had regional-specific reorganization of the cells mechanical properties similar to native lung tissue. Furthermore, both papers demonstrated that when these engineered lungs were orthotopically transplanted short-term into a recipient rat, the lungs participated in gas exchange. These two publications has since spurred many publications demonstrating reconstitution of the decellularized lung with a variety of cell types, including mesenchymal stem cells [79, 80] and fetal lung cells . The use of pluripotent stem cell-derived cells in recellularizing the lungs is promising since these cells offer an unlimited supply of autologous cells for repopulation.
In the excitement around the decellularized lung model, it is worth remembering that the adult lung is comprised of at least 40 different cell types with specialized functions including gas exchange, metabolism of xenobiotics, and immunity to name a few. Therefore, to completely recapitulate the cell lineages and functions of the lung in a decellularized model and then use these lungs as replacement organs in transplantation remains a distant horizon. However, as more studies identify methods to generate various mature lung cell types or early lung progenitor cells that can potentially differentiate into several cell lineages in vivo (Fig. 2), perhaps partial regeneration of the lung can be accomplished.
The recent success of a main stem bronchus replacement in 2008 with a decellularized human donor trachea recellularized with the recipient’s own respiratory epithelial and stem cell-derived chondrocytes  has caused much excitement in engineering bioartificial airways as replacement strategies for lung diseases. The same group recently demonstrated the clinical success of transplanting a “bioartificial nanocomposite” seeded with the patient’s bone marrow mononuclear cells that partly regenerated the tracheobronchial airway with healthy epithelium after 5 months . Long-term follow-up is yet unknown in these patients and the mechanism of how these cells regenerate remains unclear. A fuller understanding of this process might provide clues as to how to promote endogenous repopulation of other more complex organs, based around decellularized or artificial matrices.
Potential of Direct Conversion of Fibroblasts to Epithelial Cells
There is some evidence for direct conversion of fibroblasts into neurons , cardiomyocytes  and hematopoietic cells , based on the introduction of the four reprogramming transcription factors (OCT4, CMYC, SOX2, KLF4) combined with microenvironmental cues to direct lineage commitment. It is believed that the reprogramming regimen resets the epigenetic fate map of the cells rendering the cells in an epigenetically unstable state. This then allows the influence of extracellular cues such as cell culture conditions to select for or direct phenotypic changes of these cells in their new microenvironment. It has yet to be shown that this direct conversion or “transdifferentiation” of cells can be done using conditions that would support airway or lung epithelial cell growth. This avenue of research is certainly worth exploring as it could avoid the long and complex process of maturing lung cell types from embryonic precursors.
Current methods of generating lung epithelial cells from pluripotent stem cells are not 100 % efficient and cultures are often contaminated with other endodermal cell types, making it difficult to use these cells for reliable high-content drug screens and tissue regeneration. Future efforts will need to identify methods to isolate embryonic lung progenitor cells from the differentiating cultures or identify methods to generate postnatal stem cells that can differentiate into all lung cell types in vitro. In addition, in vivo assessment of the potential to functionally integrate with native cells and generate mature lung epithelial cell lineages should become the gold standard for validating any lung cell populations generated in vitro.
A.P. Wong has received research support from the Canadian Institutes of Health Research. J. Rossant has received research support from the Canadian Institutes of Health Research.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.